Business
-
Finnish drug developer Biotie Therapies has announced that it is paying $1 million for an exclusive option to acquire Neurelis, Inc., which is developing NRL-1, an intranasal diazepam formulation for the treatment of epilepsy. The… Read more . . .
-
Device manufacturer Rexam Healthcare has announced a €20 million expansion of its manufacturing operations at its site in Le Tréport, France, giving the site a total workspace of 5200 sq m. Rexam will manufacture the… Read more . . .
-
Meda has announced an expansion in its partnership with Cipla, which is already supplying azelastine for Meda’s Dymista nasal spray. With the new agreement, Meda will continue to take responsibility for clinical development and commercialization… Read more . . .
-
Irish biotech company Elan, which recently paid $1 billion to Theravance for royalty payments from sales of Breo (Relvar) Ellipta and other inhaled drugs, has been awarded an injunction against Royalty Pharma by an Irish… Read more . . .
-
According to reports, Johnson & Johnson described development of a ketamine nasal spray for the treatment of depression during a meeting with analysts on May 23, 2013. The product is not listed among the company’s… Read more . . .
-
Grifols is paying $25 million upfront, plus up to $25 million in milestone payments to acquire a worldwide license for Aradigm’s Pulmaquin and Lipoquin inhaled ciprofloxacin formulations. Grifols will also pay tiered royalties on worldwide… Read more . . .
-
Inhaled drug developer Vectura has announced better than expected preliminary results for the year ending March 31, 2013, with the company’s loss before tax 21% lower than in 2011/12. The company also announced that Paul… Read more . . .
-
According to Aegis Therapeutics, the company has been granted US Patent No. 8,440,631 for fast-acting formulations of triptans for the treatment of migraines. The patent is the second for Aegis’s triptan nasal sprays using its… Read more . . .
-
The European Patent Office will grant Insmed Incorporated EU Patent No. 1909759 for Arikace liposomal amikacin for inhalation, according to Insmed. The composition of matter patent, titled “Sustained release of anti-infective aminoglycosides,” covers formulations of… Read more . . .
-
Elan Corporation has announced that it will pay Theravance $1 billion for a 21% participation interest in future royalty payments from sales of Breo (Relvar) Ellipta, Anoro Ellipta, MABA ‘081 bifunctional muscarinic antagonist-beta2 agonist monotherapy,… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.